In COVID-19, tocilizumab reduces all-cause...

In COVID-19, tocilizumab reduces all-cause mortality at 28 d.

Abstract

SOURCE CITATION: Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;3:CD013881. 33734435.

Authors

Fernando SM; Rochwerg B

Journal

Annals of Internal Medicine, Vol. 174, No. 6,

Publisher

American College of Physicians

Publication Date

June 1, 2021

DOI

10.7326/acpj202106150-063

ISSN

1056-8751

Associated Experts

Bram Rochwerg

Associate Professor, Faculty of Health Sciences

Visit profile

Labels

In COVID-19, tocilizumab reduces all-cause mortality at 28 d.

Abstract

Authors

Journal

Publisher

Publication Date

DOI

ISSN

Associated Experts

Labels

Fields of Research (FoR)

Sustainable Development Goals (SDG)

Medical Subject Headings (MeSH)

Contact the Experts team